ReviewDiagnostic pathology2023
Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.
Review in Diagnostic pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- A novel maximum wall thickness (Tmax) category for cystic lung adenocarcinomas: a retrospective study focusing on pathological invasiveness and prognosis.Translational lung cancer research · 2026Article
- Article
- Photodynamic therapy with local-targeted perfusion for recurrent tracheal adenoid cystic carcinoma achieving 12-year survival: A case report.Oncology letters · 2026Article
- Case Report: A rare case of long-term survival in primary pulmonary adenoid cystic carcinoma with bilateral renal and chest wall metastases.Frontiers in oncology · 2026Article
- Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report.Frontiers in oncology · 2026Article
- Tracheobronchial adenoid cystic carcinoma: a two-center retrospective analysis of clinical features and survival outcomes.European journal of medical research · 2025Article
- Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review).Oncology letters · 2025Review
- Diagnosis of pulmonary adenoid cystic carcinoma using multimodal ultrasound imaging technology: A case report.Medicine · 2025Article
- Molecular genetic profiling of a rare case of primary pulmonary adenoid cystic carcinoma: Insights from whole exome sequencing and literature review.Respiratory medicine case reports · 2025Article
- Tracheal adenoid cystic carcinoma: a case report.Frontiers in oncology · 2025Article
- A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.OncoTargets and therapy · 2025Review
- Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients.Thoracic cancer · 2024Article
- Primary and Recurrent Intraosseous Adenoid Cystic Carcinoma-Analysis of Two Cases and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.Journal of neuro-oncology · 2024Article
- Lingual metastasis from primary pulmonary adenoid cystic carcinoma: A rare case report.Science progressArticle
- Impact of Interventional Bronchoscopy on Long-Term Survival in Patients with Primary Tracheal Adenoid Cystic Carcinoma: A Single-Center Experience.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPulmonary adenoid cystic carcinoma (PACC) is an exceptionally rare salivary gland-type malignant neoplasm. Because of its clinical manifestations, imaging features are not different from other types of non-small cell lung cancer, which is a diagnostic challenge for most doctors.
conclusionsA review of the literature shows that high amounts of immunohistochemical (IHC) markers, such as CK7, CD117, P63, SMA, CK5/6, and S-100 are helpful for PACC diagnosis. Surgical resection is the main treatment of PACC, but treatment options for advanced PACC patients are limited and the research of molecular targeted drugs is ongoing in advanced cases not eligible for surgery. Currently, research on PACC targeted therapy mainly focuses on the exploration of v-myb avian myeloblastosis virus oncogene homolog (MYB) and its downstream target genes. In addition, median tumor mutation burden and PD-1/PD-L1 were lower in PACC, which may indicate poor efficacy of immunotherapy in PACC patients. This review focuses on the pathologic features, molecular characteristics, diagnosis, treatment and prognosis of PACC to establish a comprehensive understanding of PACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.